1-(carboxymethylthio)tetradecane has been researched along with rosiglitazone in 1 studies
Studies (1-(carboxymethylthio)tetradecane) | Trials (1-(carboxymethylthio)tetradecane) | Recent Studies (post-2010) (1-(carboxymethylthio)tetradecane) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
---|---|---|---|---|---|
143 | 5 | 32 | 4,749 | 556 | 1,818 |
Protein | Taxonomy | 1-(carboxymethylthio)tetradecane (IC50) | rosiglitazone (IC50) |
---|---|---|---|
CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
Bile salt export pump | Homo sapiens (human) | 4.5853 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kuenzli, S; Saurat, JH | 1 |
1 trial(s) available for 1-(carboxymethylthio)tetradecane and rosiglitazone
Article | Year |
---|---|
Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfides; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |